International Myeloma Society Annual Meeting | Conference

Arlo-Cel Demonstrates Tolerability, Efficacy in R/R Myeloma

September 19th 2025

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

D-VRd Produces Favorable PROs and Safety Outcomes in MRD-Negative Newly Diagnosed Multiple Myeloma

September 19th 2025

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

Maintenance Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Produces Responses in High-Risk Myeloma

September 19th 2025

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

Iberdomide/Daratumumab/Dexamethasone Is Effective in Newly Diagnosed Multiple Myeloma

September 18th 2025

Iberdomide plus daratumumab and dexamethasone yielded deep responses and had a manageable safety profile in transplant-ineligible multiple myeloma.

Fixed-Duration Cevostamab After CAR T-Cell Therapy Is Well Tolerated in Heavily Pretreated Myeloma

September 18th 2025

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Dr San Miguel on the Association Between MRD-Negative CR and PFS/Safety in Newly Diagnosed Myeloma

September 18th 2025

Jesús San Miguel, MD, PhD, discusses patient-reported outcomes and safety for patients with newly diagnosed multiple myeloma who achieved MRD negativity and a CR or better.

Linvoseltamab Plus Carfilzomib Is Safe, Feasible, and Elicits Durable Responses in R/R Myeloma

September 18th 2025

Linvoseltamab plus carfilzomib produced expected toxicities in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Catamero on Challenges of Community-Based Administration of Bispecifics and CAR T-Cell Therapy in Myeloma

September 18th 2025

Donna Catamero, ANP-BC, OCN, CCRC, discusses the challenges community-based clinicians face in delivering bispecific antibodies and CAR T-cell therapy for multiple myeloma.

Daratumumab-Based Regimens Yield Clinical Benefit Irrespective of Frailty Changes in Newly Diagnosed, Transplant-Ineligible Myeloma

September 18th 2025

Post hoc data demonstrated benefit with daratumumab-based regimens in newly diagnosed, transplant-ineligible myeloma, regardless of frailty changes.

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma

September 18th 2025

Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

Dr Mouhieddine on the Potential Predictive Role of Ferritin Levels and ALC in Bispecific Antibody–Treated Multiple Myeloma

September 17th 2025

Tarek Mouhieddine, MD, discusses the predictive role of ferritin levels and ALC in patients with multiple myeloma receiving bispecific antibodies.

ISB 2001 Shows Favorable Safety Profile and Antitumor Activity in R/R Multiple Myeloma

September 17th 2025

ISB 2001 had a manageable safety profile and induced deep, durable responses at active doses in patients with relapsed/refractory multiple myeloma.

Dr Raab on Updated Findings With Teclistamab-Based Induction in Newly Diagnosed Multiple Myeloma

September 17th 2025

Marc S. Raab, MD, PhD, discusses the efficacy of teclistamab-based induction in patients with newly diagnosed multiple myeloma.

Cevostamab Plus Pomalidomide/Dexamethasone Is Safe, Active in R/R Myeloma

September 17th 2025

The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma

September 17th 2025

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting

September 11th 2025

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

October 2nd 2024

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

October 2nd 2024

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma

October 2nd 2024

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.

Dr Corre on MRD Negativity With D-VTd Induction/Consolidation in Newly Diagnosed Multiple Myeloma

October 2nd 2024

Jill Corre, PharmD, PhD, discusses minimal residual disease negativity rates after treatment with D-VTd induction/consolidation in newly diagnosed multiple myeloma.